Literature DB >> 10736423

Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides.

M Fukushima1, N Suzuki, T Emura, S Yano, H Kazuno, Y Tada, Y Yamada, T Asao.   

Abstract

A new class of 5-halogenated pyrimidine analogs substituted at the 6-position was evaluated as competitive inhibitors of thymidine phosphorylase (TPase). The most potent member of the series was 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidine dio ne hydrochloride (TPI), which has an apparent K(i) value of 1.7 x 10(-8) M. TPI selectively inhibited the activity of TPase, but not that of uridine phosphorylase, thymidine kinase, orotate phosphoribosyltransferase, or dihydropyrimidine dehydrogenase. In vitro inhibition studies of TPI using a thymidine analogue, 5-trifluoromethyl-2'-deoxyuridine (F(3)dThd), as the substrate demonstrated that F(3)dThd phosphorolytic activity was inhibited markedly by TPI (1 x 10(-6) M) in extracts from the liver, small intestine, and tumors of humans, from the liver and small intestine of cynomolgus monkeys, and from the liver of rodents, but not from the liver or small intestine of dogs or the small intestine of rodents, suggesting that the distribution of TPase differs between humans and animal species, and that TPI could contribute to the modulation of TPase in humans. When F(3)dThd or 5-iodo-2'-deoxyuridine (IdUrd) was coadministered to mice with TPI at a molar ratio of 1:1, the blood levels of F(3)dThd (or IdUrd) were about 2-fold higher than when F(3)dThd (or IdUrd) was administered alone. In monkeys, the maximum concentration (C(max)) and the area under the concentration-time curve (AUC) after oral F(3)dThd alone were 0.23 microg/mL and 0.28 microg. hr/mL, respectively, but markedly increased to 15.18 microg/mL (approximately 70-fold) and 28.47 microg. hr/mL (approximately 100-fold), respectively, when combined with equimolar TPI. Combined oral administration of TPI significantly potentiated the antitumor activity of F(3)dThd on AZ-521 human stomach cancer xenografts in nude mice. In conclusion, TPI may contribute not only to inhibition of TPase-mediated biological functions but also to potentiation of the biological activity of various 2'-deoxyuridine and thymidine derivatives by combining with them.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10736423     DOI: 10.1016/s0006-2952(00)00253-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  60 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

2.  Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.

Authors:  Yoshiaki Fujimoto; Ryota Nakanishi; Mamoru Nukatsuka; Kazuaki Matsuoka; Koji Ando; Takeshi Wakasa; Hiroyuki Kitao; Eiji Oki; Yoshihiko Maehara; Masaki Mori
Journal:  Cancer Chemother Pharmacol       Date:  2020-04-22       Impact factor: 3.333

3.  Combined efficacy and mechanism of trifluridine and SN-38 in a 5-FU-resistant human colorectal cancer cell lines.

Authors:  Kazuaki Matsuoka; Teiji Takechi
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

4.  Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.

Authors:  Chiara Cremolini; Daniele Rossini; Erika Martinelli; Filippo Pietrantonio; Sara Lonardi; Silvia Noventa; Emiliano Tamburini; Giovanni Luca Frassineti; Stefania Mosconi; Federico Nichetti; Sabina Murgioni; Teresa Troiani; Beatrice Borelli; Gemma Zucchelli; Alessandro Dal Maso; Vincenzo Sforza; Gianluca Masi; Carlotta Antoniotti; Maria Di Bartolomeo; Rosalba Miceli; Fortunato Ciardiello; Alfredo Falcone
Journal:  Oncologist       Date:  2018-05-08

5.  Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.

Authors:  Muhammad Wasif Saif; Lee Rosen; Michelle A Rudek; Weijing Sun; Dale R Shepard; Carlos Becerra; Fumiaki Yamashita; Paul Bebeau; Robert Winkler
Journal:  Br J Clin Pharmacol       Date:  2019-03-28       Impact factor: 4.335

6.  Transition state analysis of the arsenolytic depyrimidination of thymidine by human thymidine phosphorylase.

Authors:  Phillip A Schwartz; Mathew J Vetticatt; Vern L Schramm
Journal:  Biochemistry       Date:  2011-02-03       Impact factor: 3.162

Review 7.  Thymidine Phosphorylase in Cancer; Enemy or Friend?

Authors:  Yasir Y Elamin; Shereen Rafee; Nemer Osman; Kenneth J O Byrne; Kathy Gately
Journal:  Cancer Microenviron       Date:  2015-08-23

8.  Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Authors:  Hironori Fujii; Nobuhisa Matsuhashi; Mika Kitahora; Takao Takahashi; Chiemi Hirose; Hirotoshi Iihara; Yunami Yamada; Daichi Watanabe; Takuma Ishihara; Akio Suzuki; Kazuhiro Yoshida
Journal:  Oncologist       Date:  2019-11-20

Review 9.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

10.  Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells.

Authors:  Norihiko Suzuki; Hiroshi Tsukihara; Fumio Nakagawa; Takashi Kobunai; Teiji Takechi
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.